Antiepileptic drug interactions

Epilepsia

Volumn 41, Issue SUPPL. 8, 2000, Pages

  French, Jacqueline A ^a,c   Gidal, Barry E ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antiepileptic drug; Distribution; Drug interaction; Elimination; Inhibition

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VITAMIN D; VITAMIN K GROUP; ZONISAMIDE;

AGE; COMORBIDITY; DOSE CALCULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG URINE LEVEL; EPILEPSY; HEREDITY; HUMAN; KIDNEY FAILURE; PRIORITY JOURNAL; REVIEW;

EID: 0033753984     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.2000.tb02944.x     Document Type: Review

References (39)

1. Review of alterations in oral phenytoin bioavailability associated with formulation, antacids and food
2. Phenytoin-enteral feeding interaction
3. Absorption of drugs from the stomach. II. The human
4. Effect of food on the serum concentration profile of enteric-coated valproic acid
5. Single-dose pharmacokinetics of food on the bioavailability of topiramate, a novel antiepileptic drug
6. Tiagablne: Safety and tolerance during 2-weeks multiple dosing to healthy volunteers
7. The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers
8. Gabapentin bioavailability: Effect of dose and frequency of administration in adult patients with epilepsy
9. Multidose evaluation of gabapentin pharmacokinetics in patients with epilepsy
10. Gabapentin absorption: Effect of mixing with foods of varying macronutrient content
11. General principles: Biotransformation
12. Antiepileptic drug pharmacogenetics
13. The effect of genetic polymorphisms of CYP 2C9 and CYP 2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics
14. Pharmacogenetics and drug interactions
15. A mechanistic approach to antiepileptic drug interactions
16. Oxcarbazepine: Current status and clinical applications
17. Effect of oxcarbazepine on hepatic clearance of antipyrine in patients with previously untreated epilepsy
18. Dose-dependent enzyme induction for oxcarbazepine?
19. Oxcarbazepine: Pharmacokinetic interactions and their clinical relevance
20. Possible interaction between oxcarbazepine and an oral contraceptive
21. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: Results of a retro-spective study
22. Bidirectional interaction of valproate and lamotrigine in healthy subjects
23. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs
24. A review of vitamin K, epilepsy and pregnancy
25. Influence of rifampin and isoniazid on the kinetics of phenytoin
26. Impaired phenytoin bioavailability secondary to cisplatinum, vinblastine and bleomycine
27. Pharmacokinetic interaction of digoxin with an herbal extract from St
28. Factors influencing simultaneous concentrations of carbamazepine and its epoxide in plasma
29. Dual effect of valproic acid on the pharmacokinetics of phenytoin
30. Predicting unbound phenytoin concentrations in patients receiving valproic acid: A comparison of two prediction methods
31. Sodium valproate inhibits lamotrigine metabolism
32. Pharmacokinetic interactions with felbamate. In vitro-in vivo correlations
33. Effect of felbamate on phenytoin and carbamazepine serum concentrations
34. The effect of felbamate on valproic acid disposition
35. Potential pharmacokinetic interaction between felbamate and phenobarbital
36. Carbamazepine: Interactions with other drugs
37. Phenytoin: Interactions with other drugs: Clinical aspects
38. Phenytoin: Interactions with other drugs: Mechanistic aspects